Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK-1406 Injection
MK-1406 · 1 trial · 1 indication
Participants are evaluated for the occurrence of treatment-induced ADAs following administration of each annual dose of MK-1406.
Participants are evaluated for the occurrence of treatment-boosted ADAs following administration of each annual dose of MK-1406.
| Arm | Type | Description |
|---|---|---|
| MK-1406 | EXPERIMENTAL | Participant will receive 450 mg dose of MK-1406 (CD388) by subcutaneous (SC) injection followed 1 year later by a repeat single 450 mg dose of MK-1406 administered by SC injection. |
| Name | Type | Description |
|---|---|---|
| MK-1406 Injection | COMBINATION_PRODUCT | MK-1406 liquid for injection administered subcutaneously |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Be in stable health * Has previously completed participation in study CD388.SQ.2.05/MK-1406-004, and received a subcutaneous (SC) CD388/MK-1406 dose of either 150 mg, 300 mg or 450 mg. Exclusion Criter...
MK-1406 is an investigational small molecule being studied in healthy participants. It is currently in Phase 2 clinical development, with an active trial evaluating annual doses of MK-1406 in healthy adults. The drug is not approved and remains under investigation.
MK-1406 is being developed by Cidara Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CDTX. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug.
MK-1406 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The current Phase 2 trial is active but not recruiting participants, and the drug remains under clinical investigation.
MK-1406 is being studied in one active Phase 2 clinical trial with the identifier NCT07225959. This trial, titled 'A Study of Annual Doses of MK-1406/CD388 in Healthy Adults,' is enrolling 400 healthy participants across the United States and United Kingdom.
Yes, MK-1406 is also known as MK-1406 Injection. The drug is administered as an injection, and both names refer to the same investigational product being developed by Cidara Therapeutics for use in healthy participants.